(1)
Vassallo, C.; Canali, B.; Fiorentino, F.; Morelli, P.; Ripoli, S.; Fioravanti, L. Brentuximab Vedotin + AVD in CHL: Cost Impact on Adverse Events, Toxicity, Second Malignancies, End-of-Life and Subsequent Lines of Therapy in Italy. AboutOpen 2023, 10, 103-109.